|
|
|
|
|
|
Description:
Cellular tumor antigen p53 (Tumor suppressor p53) (Phosphoprotein p53)(Antigen NY-CO-13).
Molecular weight: 43653
View which proteins in this organism that is involved with DNA Repair;
classified after biological processes (using data from the GOA project):
DNA repair( GO:0006281 ) base-excision repair( GO:0006284 ) nucleotide-excision repair (and GO:0045001, a synonym)( GO:0006289 )
Important dates:
13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
01-JUL-1989, sequence version 2.
07-MAR-2006, entry version 101.
Phylogenetic order:
Eukaryota Metazoa Chordata Craniata Vertebrata Euteleostomi Mammalia Eutheria Euarchontoglires Primates Catarrhini Hominidae Homo.
To calculate the pI (Isoelectric point - the pH where a protein has a neutral charge),
go to this page and enter the protein ID (e.g 3MG_ECOLI): http://us.expasy.org/tools/pi_tool.html
Links to references in other databases for protein P53_HUMAN:
| Database | Pointer | Add. info#1 | Add. info#2 |
| EMBL | X02469 | CAA26306.1 | - |
| EMBL | M13121 | AAA59987.1 | - |
| EMBL | M13112 | AAA59987.1 | JOINED |
| EMBL | M13113 | AAA59987.1 | JOINED |
| EMBL | M13114 | AAA59987.1 | JOINED |
| EMBL | M13115 | AAA59987.1 | JOINED |
| EMBL | M13116 | AAA59987.1 | JOINED |
| EMBL | M13117 | AAA59987.1 | JOINED |
| EMBL | M13118 | AAA59987.1 | JOINED |
| EMBL | M13119 | AAA59987.1 | JOINED |
| EMBL | M13120 | AAA59987.1 | JOINED |
| EMBL | K03199 | AAA59989.1 | - |
| EMBL | M14694 | AAA61211.1 | - |
| EMBL | M14695 | AAA61212.1 | - |
| EMBL | M22898 | AAA59988.1 | - |
| EMBL | M22882 | AAA59988.1 | JOINED |
| EMBL | M22883 | AAA59988.1 | JOINED |
| EMBL | M22884 | AAA59988.1 | JOINED |
| EMBL | M22887 | AAA59988.1 | JOINED |
| EMBL | M22888 | AAA59988.1 | JOINED |
| EMBL | M22894 | AAA59988.1 | JOINED |
| EMBL | M22895 | AAA59988.1 | JOINED |
| EMBL | M22896 | AAA59988.1 | JOINED |
| EMBL | M22897 | AAA59988.1 | JOINED |
| EMBL | X01405 | CAA25652.1 | - |
| EMBL | X60011 | CAA42626.1 | - |
| EMBL | X60012 | CAA42627.1 | ALT_TERM |
| EMBL | X60013 | CAA42628.1 | - |
| EMBL | X60014 | CAA42629.1 | - |
| EMBL | X60015 | CAA42630.1 | - |
| EMBL | X60016 | CAA42631.1 | - |
| EMBL | X60017 | CAA42632.1 | - |
| EMBL | X60018 | CAA42633.1 | - |
| EMBL | X60019 | CAA42634.1 | - |
| EMBL | X60020 | CAA42635.1 | - |
| EMBL | AF135121 | AAD28535.1 | - |
| EMBL | AF135120 | AAD28535.1 | JOINED |
| EMBL | AF307851 | AAG28785.1 | - |
| EMBL | X54156 | CAA38095.1 | - |
| EMBL | U94788 | AAC12971.1 | - |
| EMBL | AF136271 | AAD28628.1 | - |
| EMBL | AF136270 | AAD28628.1 | JOINED |
| EMBL | AB082923 | BAC16799.1 | - |
| EMBL | AY838896 | AAV80424.1 | - |
| EMBL | BC003596 | AAH03596.1 | - |
| EMBL | AY429684 | AAR10356.1 | - |
| EMBL | AY390341 | AAQ90158.1 | - |
| EMBL | AY359814 | AAR13239.1 | - |
| EMBL | U63714 | AAB39322.1 | - |
| EMBL | AF209136 | AAF36362.1 | - |
| EMBL | AF209128 | AAF36354.1 | - |
| EMBL | AF209129 | AAF36355.1 | - |
| EMBL | AF209130 | AAF36356.1 | - |
| EMBL | AF209131 | AAF36357.1 | - |
| EMBL | AF209132 | AAF36358.1 | - |
| EMBL | AF209133 | AAF36359.1 | - |
| EMBL | AF209134 | AAF36360.1 | - |
| EMBL | AF209135 | AAF36361.1 | - |
| EMBL | AF209148 | AAF36374.1 | - |
| EMBL | AF209149 | AAF36375.1 | - |
| EMBL | AF209150 | AAF36376.1 | - |
| EMBL | AF209151 | AAF36377.1 | - |
| EMBL | AF209152 | AAF36378.1 | - |
| EMBL | AF209153 | AAF36379.1 | - |
| EMBL | AF209154 | AAF36380.1 | - |
| EMBL | AF209155 | AAF36381.1 | - |
| EMBL | AF209156 | AAF36382.1 | - |
| EMBL | AF210309 | AAF63442.1 | - |
| EMBL | AF210308 | AAF63442.1 | JOINED |
| EMBL | AF210310 | AAF63443.1 | - |
| EMBL | AF240684 | AAK76358.1 | - |
| EMBL | AF240685 | AAK76359.1 | - |
| EMBL | AY270155 | AAP30003.1 | - |
| PIR | A25224 | DNHU53. | |
| PDB | 1A1U | NMR | A/C=324-358. |
| PDB | 1AIE | X-ray | @=326-356. |
| PDB | 1C26 | X-ray | A=325-356. |
| PDB | 1DT7 | NMR | X/Y=367-388. |
| PDB | 1GZH | X-ray | A/C=-. |
| PDB | 1H26 | X-ray | E=376-386. |
| PDB | 1HS5 | NMR | A/B=324-357. |
| PDB | 1JSP | NMR | A=367-386. |
| PDB | 1KZY | X-ray | A/B=95-289. |
| PDB | 1OLG | NMR | A/B/C/D=319-360. |
| PDB | 1OLH | NMR | A/B/C/D=319-360. |
| PDB | 1PES | NMR | A/B/C/D=325-355. |
| PDB | 1PET | NMR | A/B/C/D=325-355. |
| PDB | 1SAE | NMR | A/B/C/D=319-360. |
| PDB | 1SAF | NMR | A/B/C/D=319-360. |
| PDB | 1SAG | NMR | A/B/C/D=319-360. |
| PDB | 1SAH | NMR | A/B/C/D=319-360. |
| PDB | 1SAI | NMR | A/B/C/D=319-360. |
| PDB | 1SAJ | NMR | A/B/C/D=319-360. |
| PDB | 1SAK | NMR | A/B/C/D=319-360. |
| PDB | 1SAL | NMR | A/B/C/D=319-360. |
| PDB | 1TSR | X-ray | A/B/C=94-312. |
| PDB | 1TUP | X-ray | A/B/C=94-312. |
| PDB | 1UOL | X-ray | A/B=94-312. |
| PDB | 1YCQ | X-ray | B=13-29. |
| PDB | 1YCR | X-ray | B=15-29. |
| PDB | 1YCS | X-ray | A=94-292. |
| PDB | 2B3G | X-ray | B=33-60. |
| PDB | 2BIM | X-ray | A/B=94-312. |
| PDB | 2BIN | X-ray | A=94-312. |
| PDB | 2BIO | X-ray | A=94-312. |
| PDB | 2BIP | X-ray | A=94-312. |
| PDB | 2BIQ | X-ray | A=94-312. |
| PDB | 2F1X | X-ray | A/B=-. |
| PDB | 3SAK | NMR | A/B/C/D=319-360. |
| IntAct | P04637 | -.1 | |
| TRANSFAC | T00671 | -. | |
| SWISS-2DPAGE | P04637 | HUMAN. | |
| Ensembl | ENSG00000141510 | Homo sapiens.1 | |
| H-InvDB | HIX0013510 | -.1 | |
| HGNC | HGNC:11998 | TP53.1 | |
| MIM | 133239 | phenotype. | |
| MIM | 151623 | phenotype. | |
| MIM | 191170 | gene+phenotype. | |
| MIM | 211980 | phenotype. | |
| MIM | 260500 | phenotype. | |
| MIM | 275355 | phenotype. | |
| Reactome | P04637 | -.1 | |
| LinkHub | P04637 | -.1 | |
| GO | GO:0005739 | C:mitochondrion | IDA. |
| GO | GO:0005730 | C:nucleolus | IDA. |
| GO | GO:0005524 | F:ATP binding | IDA. |
| GO | GO:0005507 | F:copper ion binding | IDA. |
| GO | GO:0000739 | F:DNA strand annealing activity | IDA. |
| GO | GO:0004518 | F:nuclease activity | TAS. |
| GO | GO:0005515 | F:protein binding | IPI. |
| GO | GO:0046982 | F:protein heterodimerization activity | IPI. |
| GO | GO:0003700 | F:transcription factor activity | IDA. |
| GO | GO:0008270 | F:zinc ion binding | TAS. |
| GO | GO:0006915 | P:apoptosis | IDA. |
| GO | GO:0006284 | P:base-excision repair | TAS. |
| GO | GO:0008635 | P:caspase activation via cytochrome c | IDA. |
| GO | GO:0007569 | P:cell aging | IMP. |
| GO | GO:0007050 | P:cell cycle arrest | TAS. |
| GO | GO:0000075 | P:cell cycle checkpoint | TAS. |
| GO | GO:0030154 | P:cell differentiation | TAS. |
| GO | GO:0008283 | P:cell proliferation | TAS. |
| GO | GO:0008630 | P:DNA damage response, signal transduction re... | TAS. |
| GO | GO:0006310 | P:DNA recombination | TAS. |
| GO | GO:0008628 | P:induction of apoptosis by hormones | TAS. |
| GO | GO:0030308 | P:negative regulation of cell growth | IMP. |
| GO | GO:0051097 | P:negative regulation of helicase activity | TAS. |
| GO | GO:0006289 | P:nucleotide-excision repair | IMP. |
| GO | GO:0051262 | P:protein tetramerization | TAS. |
| GO | GO:0046902 | P:regulation of mitochondrial membrane permea... | TAS. |
| GO | GO:0006355 | P:regulation of transcription, DNA-dependent | IDA. |
| InterPro | IPR002117 | P53. | |
| InterPro | IPR011615 | P53_DNA_bd. | |
| InterPro | IPR012346 | P53_RUNT_DNA_bd. | |
| InterPro | IPR010991 | p53_tetrameristn. | |
| Pfam | PF00870 | P53 | 1. |
| Pfam | PF07710 | P53_tetramer | 1. |
| PRINTS | PR00386 | P53SUPPRESSR. | |
| ProDom | PD002681 | P53 | 1. |
| PROSITE | PS00348 | P53 | 1. |
Keywords:
3D-structure; Acetylation; Activator; Alternative splicing; Anti-oncogene; Apoptosis; Cell cycle; Disease mutation; DNA-binding; Glycoprotein; Li-Fraumeni syndrome; Metal-binding; Nuclear protein; Phosphorylation; Polymorphism; Transcription; Transcription regulation; Zinc.
References:
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=85230577; PubMed=4006916;
RA Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
RT "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
RT cells.";
RL EMBO J. 4:1251-1255(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=87064416; PubMed=2946935;
RA Lamb P., Crawford L.;
RT "Characterization of the human p53 gene.";
RL Mol. Cell. Biol. 6:1379-1385(1986).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=85267676; PubMed=3894933;
RA Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
RT "Molecular cloning and in vitro expression of a cDNA clone for human
RT cellular tumor antigen p53.";
RL Mol. Cell. Biol. 5:1601-1610(1985).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=87089826; PubMed=3025664;
RA Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N.,
RA Rotter V.;
RT "Molecular basis for heterogeneity of the human p53 protein.";
RL Mol. Cell. Biol. 6:4650-4656(1986).
RN [5]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=89108008; PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
RA Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P.,
RA Georgiev G.P.;
RT "A variation in the structure of the protein-coding region of the
RT human p53 gene.";
RL Gene 70:245-252(1988).
RN [6]
RP NUCLEOTIDE SEQUENCE OF 101-393.
RX MEDLINE=85126934; PubMed=6396087;
RA Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L.,
RA Benchimol S.;
RT "Isolation and characterization of a human p53 cDNA clone: expression
RT of the human p53 gene.";
RL EMBO J. 3:3257-3262(1984).
RN [7]
RP NUCLEOTIDE SEQUENCE, VARIANTS BURKITT'S LYMPHOMA, AND VARIANT ARG-72.
RX MEDLINE=92007731; PubMed=1915267;
RA Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
RT "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL EMBO J. 10:2879-2887(1991).
RN [8]
RP NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72 AND LYS-286.
RX MEDLINE=93303270; PubMed=8316628;
RA Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
RA Mirzayans R.;
RT "Isolation of two cell lines from a human malignant glioma specimen
RT differing in sensitivity to radiation and chemotherapeutic drugs.";
RL Radiat. Res. 134:349-354(1993).
RN [9]
RP NUCLEOTIDE SEQUENCE, VARIANT ARG-72, AND INTERACTION WITH WWOX.
RX MEDLINE=21264809; PubMed=11058590; DOI=10.1074/jbc.M007140200;
RA Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
RA Zevotek N.;
RT "Hyaluronidase induction of a WW domain-containing oxidoreductase that
RT enhances tumor necrosis factor cytotoxicity.";
RL J. Biol. Chem. 276:3361-3370(2001).
RN [10]
RP NUCLEOTIDE SEQUENCE.
RA Chumakov P.M., Almazov V.P., Jenkins J.R.;
RL Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
RN [11]
RP NUCLEOTIDE SEQUENCE.
RA Rozemuller E.H., Tilanus M.G.J.;
RT "P53 genomic sequence. Corrections and polymorphism.";
RL Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN [12]
RP NUCLEOTIDE SEQUENCE, AND VARIANTS SER-47; ARG-72; LYS-339 AND ALA-366.
RA Livingston R.J., Rieder M.J., Chung M.-W., Ritchie T.K., Olson A.N.,
RA Nguyen C.P., Gildersleeve H., Cassidy C.M., Johnson E.J.,
RA Swanson J.E., McFarland I., Yool B., Park C., Nickerson D.A.;
RT "NIEHS-SNPs, environmental genome project, NIEHS ES15478, Department
RT of Genome Sciences, Seattle, WA (URL: http://egp.gs.washington.edu).";
RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN [13]
RP NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72 AND LYS-286.
RA Anderson C.W., Allalunis-Turner M.J.;
RT "Human TP53 from the malignant glioma-derived cell lines M059J and
RT M059K has a cancer-associated mutation in exon 8.";
RL Radiat. Res. 154:473-476(2000).
RN [14]
RP NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72; HIS-273 AND SER-309.
RA Azuma K., Shichijo S., Itoh K.;
RT "Identification of a tumor-rejection antigen recognized by HLA-B46
RT restricted CTL.";
RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN [15]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-72 AND
RP ALA-278.
RC TISSUE=Kidney;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [16]
RP NUCLEOTIDE SEQUENCE OF 1-379, AND VARIANTS ARG-72 AND ASN-139.
RC TISSUE=Lung carcinoma;
RX PubMed=14660794; DOI=10.1073/pnas.2536558100;
RA Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
RA Varga J.L.;
RT "Inhibition of mutant p53 expression and growth of DMS-153 small cell
RT lung carcinoma by antagonists of growth hormone-releasing hormone and
RT bombesin.";
RL Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
RN [17]
RP NUCLEOTIDE SEQUENCE OF 126-185.
RA Pan X.L., Zhang A.H.;
RT "Study on the effect of tumor suppressor gene p53 in arsenism
RT patients.";
RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN [18]
RP NUCLEOTIDE SEQUENCE OF 261-298.
RC TISSUE=Blood;
RA Nimri L.F., Owais W., Momani E.;
RT "Detection of P53 gene mutations and serum p53 antibodies associated
RT with cigarette smoking.";
RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN [19]
RP NUCLEOTIDE SEQUENCE OF 262-306.
RC TISSUE=Ovarian adenocarcinoma;
RA Filippini G., Soldati G.;
RL Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN [20]
RP NUCLEOTIDE SEQUENCE OF 225-260.
RC TISSUE=Glial cell, and Glial tumor;
RA Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N.,
RA Joyce K.A., Salisbury J., Sibson D.R., Vergote I., Walker C.;
RT "Mutation detection utilizing a novel PCR approach for amplification
RT of the p53 gene from microdissected tissue: application to archival
RT tumor samples.";
RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN [21]
RP NUCLEOTIDE SEQUENCE OF 225-260.
RA Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
RA Lipsky P.E.;
RT "Bcl6 and P53 gene mutations in tonsillar B cells.";
RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN [22]
RP NUCLEOTIDE SEQUENCE OF 332-366.
RA Pinto E.M., Mendonca B.B., Latronico A.C.;
RT "Allelic variant in intron 9 of TP53 gene.";
RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN [23]
RP RNA-BINDING.
RX MEDLINE=91141509; PubMed=1705009;
RA Samad A., Carroll R.B.;
RT "The tumor suppressor p53 is bound to RNA by a stable covalent
RT linkage.";
RL Mol. Cell. Biol. 11:1598-1606(1991).
RN [24]
RP ALTERNATIVE SPLICING.
RX MEDLINE=96197761; PubMed=8632903;
RA Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
RA Gilbert D., Iggo R., Frebourg T.;
RT "The human tumour suppressor gene p53 is alternatively spliced in
RT normal cells.";
RL Oncogene 12:813-818(1996).
RN [25]
RP NUCLEAR LOCALIZATION SIGNAL.
RX MEDLINE=90191730; PubMed=2156209;
RA Addison C., Jenkins J.R., Sturzbecher H.-W.;
RT "The p53 nuclear localisation signal is structurally linked to a
RT p34cdc2 kinase motif.";
RL Oncogene 5:423-426(1990).
RN [26]
RP MINIMAL REPRESSION DOMAIN.
RX MEDLINE=21125692; PubMed=11007800; DOI=10.1074/jbc.M008231200;
RA Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
RT "p53 amino acids 339-346 represent the minimal p53 repression
RT domain.";
RL J. Biol. Chem. 276:1510-1515(2001).
RN [27]
RP INTERACTION WITH ING4.
RX MEDLINE=22635239; PubMed=12750254;
RA Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
RA Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J.,
RA Harris C.C.;
RT "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
RL Cancer Res. 63:2373-2378(2003).
RN [28]
RP PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
RX MEDLINE=90280456; PubMed=2141171;
RA Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
RT "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
RL Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
RN [29]
RP DEPHOSPHORYLATION BY PP2A.
RX MEDLINE=91172186; PubMed=1848668;
RA Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
RT "Dephosphorylation of simian virus 40 large-T antigen and p53 protein
RT by protein phosphatase 2A: inhibition by small-t antigen.";
RL Mol. Cell. Biol. 11:1996-2003(1991).
RN [30]
RP O-GLYCOSYLATION.
RX MEDLINE=96197773; PubMed=8632915;
RA Shaw P., Freeman J., Bovey R., Iggo R.;
RT "Regulation of specific DNA binding by p53: evidence for a role for O-
RT glycosylation and charged residues at the carboxy-terminus.";
RL Oncogene 12:921-930(1996).
RN [31]
RP PHOSPHORYLATION BY PRPK.
RX MEDLINE=21570176; PubMed=11546806; DOI=10.1074/jbc.M105669200;
RA Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
RA Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.;
RT "Cloning and characterization of a p53-related protein kinase
RT expressed in interleukin-2-activated cytotoxic T-cells, epithelial
RT tumor cell lines, and the testes.";
RL J. Biol. Chem. 276:44003-44011(2001).
RN [32]
RP PHOSPHORYLATION SITE THR-18.
RX MEDLINE=20406546; PubMed=10951572; DOI=10.1038/sj.onc.1203709;
RA Lopez-Borges S., Lazo P.A.;
RT "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-
RT 18 within the mdm-2 binding site of the p53 tumour suppressor
RT protein.";
RL Oncogene 19:3656-3664(2000).
RN [33]
RP IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX MEDLINE=21659718; PubMed=11706030; DOI=10.1074/jbc.M108535200;
RA Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT "Differential effect of ik3-1/cables on p53- and p73-induced cell
RT death.";
RL J. Biol. Chem. 277:2951-2957(2002).
RN [34]
RP PHOSPHORYLATION SITE THR-55, MUTAGENESIS OF THR-55, AND INTERACTION
RP WITH TAF1.
RX PubMed=15053879; DOI=10.1016/S1097-2765(04)00123-6;
RA Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role
RT for TAF1 in cell G1 progression.";
RL Mol. Cell 13:867-878(2004).
RN [35]
RP ACETYLATION SITE LYS-305.
RX MEDLINE=22726738; PubMed=12724314; DOI=10.1074/jbc.M212574200;
RA Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
RT "Identification and characterization of a novel p300-mediated p53
RT acetylation site, lysine 305.";
RL J. Biol. Chem. 278:25568-25576(2003).
RN [36]
RP ACETYLATION SITES LYS-373 AND LYS-382.
RX MEDLINE=20123976; PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
RA Abraham J., Kelly J., Thibault P., Benchimol S.;
RT "Post-translational modification of p53 protein in response to
RT ionizing radiation analyzed by mass spectrometry.";
RL J. Mol. Biol. 295:853-864(2000).
RN [37]
RP DEACETYLATION OF LYS-382 BY SIRT1.
RX MEDLINE=21526627; PubMed=11672523; DOI=10.1016/S0092-8674(01)00527-X;
RA Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A.,
RA Pandita T.K., Guarente L., Weinberg R.A.;
RT "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL Cell 107:149-159(2001).
RN [38]
RP INTERACTION WITH HIPK2.
RX MEDLINE=22191252; PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA Kim E.-J., Park J.-S., Um S.-J.;
RT "Identification and characterization of HIPK2 interacting with p73 and
RT modulating functions of the p53 family in vivo.";
RL J. Biol. Chem. 277:32020-32028(2002).
RN [39]
RP INTERACTION WITH HIPK2, PHOSPHORYLATION SITE SER-46, AND MUTAGENESIS
RP OF SER-46 AND LYS-382.
RX MEDLINE=21638685; PubMed=11740489; DOI=10.1038/ncb715;
RA Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA Will H., Schmitz M.L.;
RT "Regulation of p53 activity by its interaction with homeodomain-
RT interacting protein kinase-2.";
RL Nat. Cell Biol. 4:1-10(2002).
RN [40]
RP INTERACTION WITH HIPK2, AND PHOSPHORYLATION SITE SER-46.
RX MEDLINE=21638694; PubMed=11780126; DOI=10.1038/ncb714;
RA D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y.,
RA Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G.,
RA Fanciulli M., Appella E., Soddu S.;
RT "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46
RT and mediates apoptosis.";
RL Nat. Cell Biol. 4:11-19(2002).
RN [41]
RP INTERACTION WITH P53DINP1.
RX MEDLINE=22863074; PubMed=12851404; DOI=10.1074/jbc.M301979200;
RA Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
RA Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT partners in regulating p53 activity.";
RL J. Biol. Chem. 278:37722-37729(2003).
RN [42]
RP INTERACTION WITH HIPK1.
RX MEDLINE=22608637; PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
RA Mak T.W., Thukral S.K.;
RT "Characterization of cells and gene-targeted mice deficient for the
RT p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN [43]
RP INTERACTIONS WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
RX PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA An W., Kim J., Roeder R.G.;
RT "Ordered cooperative functions of PRMT1, p300, and CARM1 in
RT transcriptional activation by p53.";
RL Cell 117:735-748(2004).
RN [44]
RP NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
RX MEDLINE=22825602; PubMed=12944468;
RX DOI=10.1128/MCB.23.18.6396-6405.2003;
RA O'Keefe K., Li H., Zhang Y.;
RT "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
RT cytoplasmic degradation but not ubiquitination.";
RL Mol. Cell. Biol. 23:6396-6405(2003).
RN [45]
RP INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46.
RX PubMed=16219768; DOI=10.1074/jbc.M505590200;
RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT "WOX1 is essential for tumor necrosis factor-, UV light-,
RT staurosporine-, and p53-mediated cell death, and its tyrosine 33-
RT phosphorylated form binds and stabilizes serine 46-phosphorylated
RT p53.";
RL J. Biol. Chem. 280:43100-43108(2005).
RN [46]
RP REVIEW ON ZINC-BINDING PROPERTIES.
RX MEDLINE=21438235; PubMed=11554448; DOI=10.1089/15230860152542961;
RA Hainaut P., Mann K.;
RT "Zinc binding and redox control of p53 structure and function.";
RL Antioxid. Redox Signal. 3:611-623(2001).
RN [47]
RP STRUCTURE BY NMR OF 319-360.
RX MEDLINE=94294808; PubMed=8023159;
RA Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
RA Appella E., Gronenborn A.M.;
RT "High-resolution structure of the oligomerization domain of p53 by
RT multidimensional NMR.";
RL Science 265:386-391(1994).
RN [48]
RP STRUCTURE BY NMR OF 325-355.
RX MEDLINE=95292092; PubMed=7773777;
RA Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
RT "Solution structure of the tetrameric minimum transforming domain of
RT p53.";
RL Nat. Struct. Biol. 1:877-890(1994).
RN [49]
RP STRUCTURE BY NMR OF 326-354.
RX MEDLINE=98026899; PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
RA McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
RA Halazonetis T.D.;
RT "Hydrophobic side-chain size is a determinant of the three-dimensional
RT structure of the p53 oligomerization domain.";
RL EMBO J. 16:6230-6236(1997).
RN [50]
RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
RX MEDLINE=94294806; PubMed=8023157;
RA Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
RT "Crystal structure of a p53 tumor suppressor-DNA complex:
RT understanding tumorigenic mutations.";
RL Science 265:346-355(1994).
RN [51]
RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
RX MEDLINE=95184011; PubMed=7878469;
RA Jeffrey P.D., Gorina S., Pavletich N.P.;
RT "Crystal structure of the tetramerization domain of the p53 tumor
RT suppressor at 1.7 angstroms.";
RL Science 267:1498-1502(1995).
RN [52]
RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
RX MEDLINE=97081050; PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
RA Levine A.J., Pavletich N.P.;
RT "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT transactivation domain.";
RL Science 274:948-953(1996).
RN [53]
RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
RX MEDLINE=97035414; PubMed=8875926; DOI=10.1126/science.274.5289.1001;
RA Gorina S., Pavletich N.P.;
RT "Structure of the p53 tumor suppressor bound to the ankyrin and SH3
RT domains of 53BP2.";
RL Science 274:1001-1005(1996).
RN [54]
RP REVIEW.
RX MEDLINE=94090335; PubMed=8266092;
RA Harris C.C.;
RT "p53: at the crossroads of molecular carcinogenesis and risk
RT assessment.";
RL Science 262:1980-1981(1993).
RN [55]
RP REVIEW ON VARIANTS.
RX MEDLINE=91289156; PubMed=1905840;
RA Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
RT "p53 mutations in human cancers.";
RL Science 253:49-53(1991).
RN [56]
RP REVIEW ON VARIANTS.
RX MEDLINE=96271983; PubMed=8829653;
RX DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5;
RA de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
RA Liao D., Soussi T., Kovach J.S., Sommer S.S.;
RT "Database of mutations in the p53 and APC tumor suppressor genes
RT designed to facilitate molecular epidemiological analyses.";
RL Hum. Mutat. 7:202-213(1996).
RN [57]
RP VARIANT ARG-72.
RX MEDLINE=91153807; PubMed=1999338; DOI=10.1007/BF00201836;
RA Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
RT "Characterization of a frequent polymorphism in the coding sequence of
RT the Tp53 gene in colonic cancer patients and a control population.";
RL Hum. Genet. 86:369-370(1991).
RN [58]
RP VARIANT LFS THR-133.
RX MEDLINE=92034774; PubMed=1933902;
RA Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
RT "A germ line mutation in exon 5 of the p53 gene in an extended cancer
RT family.";
RL Cancer Res. 51:6385-6387(1991).
RN [59]
RP VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
RX MEDLINE=91057657; PubMed=1978757;
RA Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E.,
RA Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A.,
RA Friend S.H.;
RT "Germ line p53 mutations in a familial syndrome of breast cancer,
RT sarcomas, and other neoplasms.";
RL Science 250:1233-1238(1990).
RN [60]
RP VARIANT LFS ASP-245.
RX MEDLINE=91080929; PubMed=2259385; DOI=10.1038/348747a0;
RA Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
RT "Germ-line transmission of a mutated p53 gene in a cancer-prone family
RT with Li-Fraumeni syndrome.";
RL Nature 348:747-749(1990).
RN [61]
RP VARIANT LFS LEU-272.
RX MEDLINE=92147883; PubMed=1737852;
RA Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I.,
RA Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J.,
RA Knutsen T., Minna J.D.;
RT "Hereditary and acquired p53 gene mutations in childhood acute
RT lymphoblastic leukemia.";
RL J. Clin. Invest. 89:640-647(1992).
RN [62]
RP VARIANTS LFS HIS-273 AND VAL-325.
RX MEDLINE=92228023; PubMed=1565144;
RA Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H.,
RA Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J.,
RA Strong L.C.;
RT "Germline mutations of the p53 tumor-suppressor gene in children and
RT young adults with second malignant neoplasms.";
RL N. Engl. J. Med. 326:1309-1315(1992).
RN [63]
RP VARIANTS BREAST TUMORS GLN-132; SER-249; LYS-280 AND LYS-285.
RX MEDLINE=90295284; PubMed=1694291;
RA Bartek J., Iggo R., Gannon J., Lane D.P.;
RT "Genetic and immunochemical analysis of mutant p53 in human breast
RT cancer cell lines.";
RL Oncogene 5:893-899(1990).
RN [64]
RP VARIANTS COLON TUMORS PHE-241 AND HIS-273.
RX MEDLINE=91017544; PubMed=1699228;
RA Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
RA Gannon J.V., Lane D.P.;
RT "p53 mutations in colorectal cancer.";
RL Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
RN [65]
RP VARIANTS ESOPHAGUS TUMOR VAL-154; VAL-245; GLN-248; LEU-278 AND
RP SER-278.
RX MEDLINE=91088630; PubMed=2263646;
RA Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
RT "Frequent mutation of the p53 gene in human esophageal cancer.";
RL Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
RN [66]
RP VARIANTS COLORECTAL CANCER MUTATIONS.
RX MEDLINE=91282784; PubMed=1647768;
RA Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
RA Wakui A., Yamazaki T.;
RT "Mutations of the P53 gene, including an intronic point mutation, in
RT colorectal tumors.";
RL Biochem. Biophys. Res. Commun. 177:901-906(1991).
RN [67]
RP VARIANTS ESOPHAGUS TUMORS LEU-152; ALA-155; HIS-175; PHE-176 AND
RP HIS-273.
RX MEDLINE=91330175; PubMed=1868473;
RA Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B.,
RA Roth J.A.;
RT "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
RL Cancer Res. 51:4495-4499(1991).
RN [68]
RP VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN CHINA.
RX MEDLINE=91187113; PubMed=1849234; DOI=10.1038/350427a0;
RA Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
RT "Mutational hotspot in the p53 gene in human hepatocellular
RT carcinomas.";
RL Nature 350:427-428(1991).
RN [69]
RP VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN SOUTH AFRICA.
RX MEDLINE=91187114; PubMed=1672732; DOI=10.1038/350429a0;
RA Bressac B., Kew M., Wands J., Ozturk M.;
RT "Selective G to T mutations of p53 gene in hepatocellular carcinoma
RT from southern Africa.";
RL Nature 350:429-431(1991).
RN [70]
RP VARIANTS HNSCC PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273.
RX MEDLINE=93007999; PubMed=1394225;
RA Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA Casey G.;
RT "Frequent p53 mutations in head and neck cancer.";
RL Cancer Res. 52:5997-6000(1992).
RN [71]
RP VARIANTS ANOGENITAL CARCINOMAS.
RX MEDLINE=93010989; PubMed=1327751;
RA Crook T., Vousden K.H.;
RT "Properties of p53 mutations detected in primary and secondary
RT cervical cancers suggest mechanisms of metastasis and involvement of
RT environmental carcinogens.";
RL EMBO J. 11:3935-3940(1992).
RN [72]
RP VARIANTS ORAL SQUAMOUS CELL CARCINOMA CYS-205; GLU-281 AND LYS-285.
RX MEDLINE=93093790; PubMed=1459726;
RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
RA Yamamoto H., Tsuchida N.;
RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral
RT squamous-cell carcinoma.";
RL Int. J. Cancer 52:867-872(1992).
RN [73]
RP VARIANT PRO-HIS-PRO-178 INS.
RX MEDLINE=93265016; PubMed=1303181;
RA Bhatia K., Guiterrez M.I., Magrath I.T.;
RT "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
RL Hum. Mol. Genet. 1:207-208(1992).
RN [74]
RP VARIANTS BURKITT'S LYMPHOMAS.
RX MEDLINE=93064692; PubMed=1437144;
RA Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
RA Appella E., May P.;
RT "p53 mutations in Raji cells: characterization and localization
RT relative to other Burkitt's lymphomas.";
RL Oncogene 7:2161-2167(1992).
RN [75]
RP VARIANT NASOPHARYNGEAL CARCINOMA THR-280.
RX MEDLINE=92335329; PubMed=1631151;
RA Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Cao Y.,
RA Yao K.-T., Colburn N.H.;
RT "An infrequent point mutation of the p53 gene in human nasopharyngeal
RT carcinoma.";
RL Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
RN [76]
RP VARIANTS HNSCC.
RX MEDLINE=93235942; PubMed=7682763;
RA Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
RT "p53 alterations in human squamous cell carcinomas and carcinoma cell
RT lines.";
RL Am. J. Pathol. 142:1131-1139(1993).
RN [77]
RP VARIANTS HNSCC.
RX MEDLINE=94006220; PubMed=8402617;
RA Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
RA Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
RT "The incidence of p53 mutations increases with progression of head and
RT neck cancer.";
RL Cancer Res. 53:4477-4480(1993).
RN [78]
RP VARIANTS COLON TUMORS.
RX MEDLINE=93330562; PubMed=8336944;
RA Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
RT "Efficient screening of p53 mutations by denaturing gradient gel
RT electrophoresis in colorectal tumors.";
RL Oncogene 8:2213-2220(1993).
RN [79]
RP CHARACTERIZATION OF VARIANT ALA-143.
RX MEDLINE=94283378; PubMed=8013454;
RA Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
RT "A temperature-sensitive mutant of human p53.";
RL EMBO J. 13:2535-2544(1994).
RN [80]
RP VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
RX MEDLINE=95193787; PubMed=7887414;
RA Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
RA Fraumeni J.F. Jr., Li F.P., Friend S.H.;
RT "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
RL Am. J. Hum. Genet. 56:608-615(1995).
RN [81]
RP VARIANT LFS HIS-175.
RX MEDLINE=96423319; PubMed=8825920;
RA Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
RA Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M.,
RA Evans D.G.R.;
RT "An extended Li-Fraumeni kindred with gastric carcinoma and a codon
RT 175 mutation in TP53.";
RL J. Med. Genet. 32:942-945(1995).
RN [82]
RP VARIANTS ESOPHAGEAL ADENOCARCINOMA PHE-176; SER-245; TRP-248; TRP-282
RP AND GLN-286.
RX MEDLINE=96233927; PubMed=8829627;
RX DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0;
RA Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B.,
RA Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
RT "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
RL Hum. Mutat. 7:109-113(1996).
RN [83]
RP VARIANTS COLORECTAL TUMORS.
RX MEDLINE=97255965; PubMed=9101296;
RX DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7;
RA Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
RA Zeuthen J.;
RT "Single-step DGGE-based mutation scanning of the p53 gene: application
RT to genetic diagnosis of colorectal cancer.";
RL Hum. Mutat. 9:348-355(1997).
RN [84]
RP VARIANT COLORECTAL CARCINOMA ILE-157.
RX MEDLINE=98080146; PubMed=9419979; DOI=10.1038/sj.onc.1201668;
RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
RT "Drastic genetic instability of tumors and normal tissues in Turcot
RT syndrome.";
RL Oncogene 15:2877-2881(1997).
RN [85]
RP VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273
RP AND SER-278.
RX MEDLINE=98111377; PubMed=9450901;
RX DOI=10.1002/(SICI)1098-1004(1998)11:1<39::AID-HUMU6>3.0.CO;2-G;
RA van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
RA Raubenheimer E.J.;
RT "Detection of p53 gene mutations in oral squamous cell carcinomas of a
RT black African population sample.";
RL Hum. Mutat. 11:39-44(1998).
RN [86]
RP VARIANT NONCLASSICAL LFS CYS-337.
RX MEDLINE=98112421; PubMed=9452042;
RA Luca J.W., Strong L.C., Hansen M.F.;
RT "A germline missense mutation R337C in exon 10 of the human p53
RT gene.";
RL Hum. Mutat. Suppl. 1:S58-S61(1998).
RN [87]
RP VARIANT LFS ILE-292.
RX MEDLINE=99414637; PubMed=10484981; DOI=10.1016/S0165-4608(98)00276-3;
RA Gueran S., Tunca Y., Imirzalioglu N.;
RT "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in
RT a Li-Fraumeni syndrome family.";
RL Cancer Genet. Cytogenet. 113:145-151(1999).
RN [88]
RP INVOLVEMENT IN CHOROID PLEXUS PAPILLOMA.
RX MEDLINE=22079076; PubMed=12085209; DOI=10.1038/sj/bjc/6600269;
RA Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P.,
RA Taylor G.R., Lu X., Barnes D.M., Camplejohn R.S.;
RT "Investigations on a clinically and functionally unusual and novel
RT germline p53 mutation.";
RL Br. J. Cancer 86:1592-1596(2002).
Feature:
CHAIN 1 393 Cellular tumor antigen p53.
/FTId=PRO_0000185703.
DNA_BIND 102 292
REGION 1 83 Interaction with HRMT1L2.
REGION 1 44 Transcription activation (acidic).
REGION 66 110 Interaction with WWOX.
REGION 100 370 Interaction with HIPK1 (By similarity).
REGION 116 292 Interaction with AXIN1 (By similarity).
REGION 241 248 Interacts with the 53BP2 SH3 domain.
REGION 300 393 Interaction with CARM1.
REGION 319 360 Interaction with HIPK2.
REGION 325 356 Oligomerization.
REGION 368 387 Basic (repression of DNA-binding).
MOTIF 305 321 Bipartite nuclear localization signal.
MOTIF 339 350 Nuclear export signal.
METAL 176 176 Zinc.
METAL 179 179 Zinc.
METAL 238 238 Zinc.
METAL 242 242 Zinc.
BINDING 392 392 5'-phospho-RNA (covalent).
MOD_RES 15 15 Phosphoserine (by PRPK).
MOD_RES 18 18 Phosphothreonine (by VRK1).
MOD_RES 46 46 Phosphoserine (by HIPK2).
MOD_RES 55 55 Phosphothreonine (by TAF1).
MOD_RES 305 305 N6-acetyllysine.
MOD_RES 315 315 Phosphoserine (by CDC2).
MOD_RES 373 373 N6-acetyllysine.
MOD_RES 382 382 N6-acetyllysine.
VARSPLIC 332 341 IRGRERFEMF -> DGTSFQKENC (in isoform 2).
/FTId=VSP_006535.
VARSPLIC 342 393 Missing (in isoform 2).
/FTId=VSP_006536.
VARIANT 7 7 D -> H (in a skin tumor).
/FTId=VAR_005851.
VARIANT 35 35 L -> F (in a liver tumor).
/FTId=VAR_005852.
VARIANT 43 43 L -> S (in a renal tumor).
/FTId=VAR_005853.
VARIANT 47 47 P -> S (in dbSNP:1800371).
/FTId=VAR_014632.
VARIANT 53 53 W -> C (in a leukemia and a lymphoma).
/FTId=VAR_005854.
VARIANT 60 60 P -> S (in a leukemia and a lymphoma).
/FTId=VAR_005855.
VARIANT 72 72 P -> R (in dbSNP:1042522).
/FTId=VAR_005856.
VARIANT 79 79 A -> T (in clone P53-H-1).
/FTId=VAR_005857.
VARIANT 87 87 P -> Q (in a brain tumor).
/FTId=VAR_005858.
VARIANT 94 94 S -> T (in a colon tumor).
/FTId=VAR_005859.
VARIANT 110 110 R -> C (in a liver and an uterus tumor).
/FTId=VAR_005860.
VARIANT 110 110 R -> L (in a liver tumor).
/FTId=VAR_005861.
VARIANT 110 110 R -> P (in a breast tumor).
/FTId=VAR_005862.
VARIANT 113 113 F -> C (in a lung tumor).
/FTId=VAR_005863.
VARIANT 125 125 T -> M (in a lung tumor).
/FTId=VAR_005864.
VARIANT 126 126 Y -> D (in a colorectal tumor).
/FTId=VAR_005865.
VARIANT 126 126 Y -> N (in a leukemia and a lymphoma).
/FTId=VAR_005866.
VARIANT 127 127 S -> F (in a lung tumor).
/FTId=VAR_005867.
VARIANT 128 128 P -> S (in a breast tumor).
/FTId=VAR_005868.
VARIANT 129 129 A -> D (in a sarcoma).
/FTId=VAR_005869.
VARIANT 130 130 L -> R (in a liver tumor).
/FTId=VAR_005870.
VARIANT 131 131 N -> K (in a colon tumor).
/FTId=VAR_005872.
VARIANT 131 131 N -> S (in a liver tumor).
/FTId=VAR_005871.
VARIANT 132 132 K -> M (in a sarcoma).
/FTId=VAR_005873.
VARIANT 132 132 K -> Q (in a breast tumor).
/FTId=VAR_005874.
VARIANT 133 133 M -> T (in LFS).
/FTId=VAR_005875.
VARIANT 135 135 C -> F (in a colon tumor).
/FTId=VAR_005877.
VARIANT 135 135 C -> S (in a colon tumor).
/FTId=VAR_005876.
VARIANT 136 136 Q -> E (in a breast tumor).
/FTId=VAR_005878.
VARIANT 136 136 Q -> K (in a colon tumor).
/FTId=VAR_005879.
VARIANT 137 137 L -> Q (in a liver tumor).
/FTId=VAR_005880.
VARIANT 138 138 A -> P (in a lung tumor).
/FTId=VAR_005881.
VARIANT 139 139 K -> N (in a breast, an ovary tumor, a
leukemia and a lymphoma).
/FTId=VAR_005882.
VARIANT 141 141 C -> F (in a breast tumor).
/FTId=VAR_005885.
VARIANT 141 141 C -> G (in an ovary tumor).
/FTId=VAR_005884.
VARIANT 141 141 C -> Y (in many types of tumors).
/FTId=VAR_005886.
VARIANT 143 143 V -> A (in a colon tumor; strong DNA
binding ability at 32.5 degrees Celsius;
strong reduction of transcriptional
activity at 37.5 degrees Celsius).
/FTId=VAR_005887.
VARIANT 144 144 Q -> P (in a leukemia and a lymphoma).
/FTId=VAR_005888.
VARIANT 145 145 L -> P (in a brain tumor).
/FTId=VAR_005889.
VARIANT 145 145 L -> Q (in an esophagus tumor).
/FTId=VAR_005890.
VARIANT 147 147 V -> D (in an ovary tumor).
/FTId=VAR_005891.
VARIANT 147 147 V -> G (in a prostate tumor).
/FTId=VAR_005892.
VARIANT 149 149 S -> P (in a breast tumor).
/FTId=VAR_005893.
VARIANT 151 151 P -> A (in a brain and a colon tumor).
/FTId=VAR_005894.
VARIANT 151 151 P -> S (in many types of tumors).
/FTId=VAR_005895.
VARIANT 151 151 P -> T (in a breast tumor).
/FTId=VAR_005896.
VARIANT 152 152 P -> L (in an esophagus tumor).
/FTId=VAR_005897.
VARIANT 152 152 P -> S (in oral squamous cell carcinoma).
/FTId=VAR_005898.
VARIANT 153 153 P -> T (in a colon tumor).
/FTId=VAR_005899.
VARIANT 154 154 G -> V (in esophagus tumor).
/FTId=VAR_005900.
VARIANT 155 155 T -> A (in an esophagus tumor).
/FTId=VAR_005901.
VARIANT 156 156 R -> P (in an osteosarcoma cell line).
/FTId=VAR_005902.
VARIANT 157 157 V -> D (in a liver tumor).
/FTId=VAR_005903.
VARIANT 157 157 V -> F (in a South African hepatocellular
carcinoma).
/FTId=VAR_005904.
VARIANT 157 157 V -> I (in colorectal carcinoma; from a
patient with Turcot syndrome).
/FTId=VAR_012977.
VARIANT 158 158 R -> C (in a noninvasive head and neck
tumor).
/FTId=VAR_005905.
VARIANT 158 158 R -> G (in a brain and a lung tumor).
/FTId=VAR_005906.
VARIANT 158 158 R -> H (in many types of tumors).
/FTId=VAR_005907.
VARIANT 160 160 M -> I (in a lung and a skin tumor).
/FTId=VAR_005908.
VARIANT 161 161 A -> S (in a brain tumor).
/FTId=VAR_005909.
VARIANT 162 162 I -> S (in a brain tumor).
/FTId=VAR_005910.
VARIANT 162 162 I -> V (in an ovary tumor).
/FTId=VAR_005911.
VARIANT 163 163 Y -> H (in HNSCC).
/FTId=VAR_005912.
VARIANT 164 164 K -> N (in a lung tumor).
/FTId=VAR_005913.
VARIANT 164 164 K -> Q (in a breast tumor).
/FTId=VAR_005914.
VARIANT 165 165 Q -> L (in a breast tumor).
/FTId=VAR_005915.
VARIANT 165 165 Q -> R (in an ovary tumor).
/FTId=VAR_005916.
VARIANT 166 166 S -> L (in a lung tumor).
/FTId=VAR_005917.
VARIANT 168 168 H -> R (in a brain tumor).
/FTId=VAR_005918.
VARIANT 169 169 M -> I (in oral squamous cell carcinoma).
/FTId=VAR_005919.
VARIANT 169 169 M -> T (in a noninvasive head and neck
tumor).
/FTId=VAR_005920.
VARIANT 170 170 T -> M (in a colon tumor).
/FTId=VAR_005921.
VARIANT 170 170 T -> S (in a colon tumor).
/FTId=VAR_005922.
VARIANT 172 172 V -> A (in a prostate tumor).
/FTId=VAR_005923.
VARIANT 173 173 V -> E (in a colon tumor).
/FTId=VAR_005924.
VARIANT 173 173 V -> L (in a cervical carcinoma).
/FTId=VAR_005925.
VARIANT 173 173 V -> M (in a colon tumor).
/FTId=VAR_005926.
VARIANT 174 174 R -> H (in the cell line Detroit 562 of
squamous cell carcinoma).
/FTId=VAR_005927.
VARIANT 175 175 R -> C (in a colon and an uterus tumor).
/FTId=VAR_005928.
VARIANT 175 175 R -> G (in a brain tumor).
/FTId=VAR_005929.
VARIANT 175 175 R -> H (in LFS and colon/esophagus/
gastric tumors).
/FTId=VAR_005932.
VARIANT 175 175 R -> L (in a breast and a colon tumor).
/FTId=VAR_005930.
VARIANT 175 175 R -> P (in a cervical carcinoma).
/FTId=VAR_005931.
VARIANT 176 176 C -> F (in esophagus tumors and many
types of tumors).
/FTId=VAR_005933.
VARIANT 176 176 C -> W (in a lung tumor).
/FTId=VAR_005934.
VARIANT 177 177 P -> L (in a skin tumor).
/FTId=VAR_005935.
VARIANT 178 178 H -> HPHP (in a Burkitt's lymphoma).
/FTId=VAR_005936.
VARIANT 181 181 R -> L (in a cervical carcinoma).
/FTId=VAR_005937.
VARIANT 182 182 C -> S (in a stomach tumor).
/FTId=VAR_005938.
VARIANT 184 184 D -> Y (in a leukemia and a lymphoma).
/FTId=VAR_005939.
VARIANT 186 186 D -> Y (in a breast tumor).
/FTId=VAR_005940.
VARIANT 187 187 G -> C (in a breast tumor).
/FTId=VAR_005941.
VARIANT 187 187 G -> S (in a leukemia and a lymphoma).
/FTId=VAR_005942.
VARIANT 189 189 A -> P (in an ovary tumor).
/FTId=VAR_005943.
VARIANT 190 190 P -> L (in a colorectal tumor).
/FTId=VAR_005944.
VARIANT 191 191 P -> T (in a colon tumor).
/FTId=VAR_005945.
VARIANT 192 192 Q -> R (in a colon tumor).
/FTId=VAR_005946.
VARIANT 193 193 H -> D (in an uterus tumor).
/FTId=VAR_005947.
VARIANT 193 193 H -> R (in LFS).
/FTId=VAR_005948.
VARIANT 194 194 L -> P (in a colon tumor).
/FTId=VAR_005949.
VARIANT 194 194 L -> R (in the cell line HU 281 of
squamous cell carcinoma).
/FTId=VAR_005950.
VARIANT 195 195 I -> T (in oral squamous cell carcinoma).
/FTId=VAR_005951.
VARIANT 198 198 E -> K (in HNSCC).
/FTId=VAR_005952.
VARIANT 205 205 Y -> C (in oral squamous cell carcinoma).
/FTId=VAR_005953.
VARIANT 205 205 Y -> D (in HNSCC).
/FTId=VAR_005954.
VARIANT 213 213 R -> Q (in a Burkitt's lymphoma and a
colorectal tumor).
/FTId=VAR_005955.
VARIANT 216 216 V -> M (in HNSCC).
/FTId=VAR_005956.
VARIANT 220 220 Y -> C (in oral squamous cell carcinoma).
/FTId=VAR_005957.
VARIANT 220 220 Y -> H (in a colon tumor).
/FTId=VAR_005958.
VARIANT 220 220 Y -> S (in HNSCC).
/FTId=VAR_005959.
VARIANT 228 228 D -> E (in HNSCC).
/FTId=VAR_005960.
VARIANT 230 230 T -> I (in oral squamous cell carcinoma).
/FTId=VAR_005961.
VARIANT 232 232 I -> T (in an anal tumor).
/FTId=VAR_005962.
VARIANT 234 234 Y -> C (in HNSCC).
/FTId=VAR_005963.
VARIANT 234 234 Y -> H (in a Burk